140 related articles for article (PubMed ID: 16138935)
1. Beyond statin therapy: why we need new thinking.
Assmann G
Curr Med Res Opin; 2005; 21 Suppl 6():S3-8. PubMed ID: 16138935
[TBL] [Abstract][Full Text] [Related]
2. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
3. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
4. Statins and LDL-cholesterol lowering: an overview.
Stroes E
Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
[TBL] [Abstract][Full Text] [Related]
5. Low HDL-C: a secondary target of dyslipidemia therapy.
Rosenson RS
Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
[TBL] [Abstract][Full Text] [Related]
6. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
7. Lipid abnormalities and cardiovascular risk in the elderly.
Milionis HJ; Elisaf MS; Mikhailidis DP
Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
[TBL] [Abstract][Full Text] [Related]
8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
10. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
13. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
Chapman MJ
Curr Med Res Opin; 2005; 21 Suppl 6():S17-22. PubMed ID: 16138937
[TBL] [Abstract][Full Text] [Related]
14. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
15. Treating dyslipidemia in the high-risk patient.
Jones PH
J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
[TBL] [Abstract][Full Text] [Related]
16. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
17. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
18. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
19. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Hobbs FD
Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
[TBL] [Abstract][Full Text] [Related]
20. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Rosenson RS
Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]